Tapazole Related Published Studies
Well-designed clinical trials related to Tapazole (Methimazole)
Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. [2007.06]
Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: an evaluation by a randomized trial. [2006.08]
Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. [2005.05]
Serum thyrotropin-receptor autoantibodies levels after I therapy in Graves' patients: effect of pretreatment with methimazole evaluated by a prospective, randomized study. [2004.10]
Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism. [2004.06]
Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. [2003.12]
Efficacy and safety of once versus twice daily administration of methimazole in cats with hyperthyroidism. [2003.04.01]
Bioavailability of transdermal methimazole in a pluronic lecithin organogel (PLO) in healthy cats. [2002.06]
The effect of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism: a randomized clinical trial. [2002.02]
The effect of methimazole on thyroid uptake of pertechnetate and radioiodine in normal cats. [2001.09]
The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study. [2001.08]
Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism. [2001.03]
[Clinical observation on treatment of thyrotoxic exophthalmos with jiayanxiao plus tapazole] [2000.06]
Medical therapy of Graves' disease: effect on remission rates of methimazole alone and in combination with triiodothyronine. [2000.02]
Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism. [1999.11]
Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. [1998.10]
Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease. [1998.03]
Treatment of hyperthyroidism with a small single daily dose of methimazole: a prospective long-term follow-up study. [1997.08]
Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease. [1996.09]
Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. [1996.09]
[Effect of methimazole and dexamethasone on leucocyte glucocorticoid receptor, plasma ACTH, and cortisol levels in Graves' disease] [1996.03]
Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin-2 receptor, and beta 2-microglobulin in patients with Graves' disease. [1996.02]
Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. [1995.09]
Response to methimazole in Graves' disease. The European Multicenter Study Group. [1995.09]
Short-term treatment of Graves' disease with methimazole in high versus low doses. [1995.08]
The action of methimazole and L-thyroxine in radioiodine therapy: a prospective study on the incidence of hypothyroidism. [1995.02]
The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. [1994.08]
Treatment of hyperthyroidism with a small single daily dose of methimazole. [1988.09]
Well-designed clinical trials possibly related to Tapazole (Methimazole)
Low doses of cholestyramine in the treatment of hyperthyroidism. [2008.10.23]
The use of konjac glucomannan to lower serum thyroid hormones in hyperthyroidism. [2007.12]
[Clinical effect of prunrllae oral solution in treating hyperthyrea] [2007.08]
Favorable clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinical hyperthyroidism. [2007.03]
[Observation on therapeutic effect of picking therapy on Graves' disease] [2006.11]
Thyroid hormone increases mannan-binding lectin levels. [2005.11]
The effect of antioxidant supplementation on superoxide dismutase activity, Cu and Zn levels, and total antioxidant status in erythrocytes of patients with Graves' disease. [2005]
Supplementation with antioxidants in the treatment of Graves' disease; the effect on glutathione peroxidase activity and concentration of selenium. [2004.03]
[Assessment of early immunosuppressive therapy in the prevention of complications of Graves' disease] [2004]
[Clinical observation on xiehuo yangyin powder in treating 30 initial stage of toxic and diffuse goiter patients] [2003.11]
Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease. [2002.10]
[Treatment of hyperthyroid atrial fibrillation associated with Graves disease by prednisone] [2002.06.25]
The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease. [2001.07]
[Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs] [2001.03.10]
Oxygen consumption in patients with hyperthyroidism before and after treatment with beta-blockade versus thyrostatic treatment: a prospective randomized study. [2001.01]
[Clinical study on hyperthyroidism of yang hyperactivity type due to yin deficiency treated by jiakang ning capsule] [1999.03]
Role of colestipol in the treatment of hyperthyroidism. [1998.12]
Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. [1998.08]
[Substrate metabolism in untreated and treated thyrotoxicosis] [1998.03.02]
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. [1998.01.08]
Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease. [1997.10]
Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis. [1997.09]
[Therapeutic effect and its mechanism exploration on mainly using traditional Chinese medicine of replenishing qi and nourishing yin in treating Graves disease] [1997.06]
[A study on observation of bone metabolism in middle-aged and senile female Graves' disease] [1996.08]
Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease. [1996.06]
Effect of intravenous gammaglobulin on organ specific antibodies and lymphocyte subsets. [1996.05]
Glucose turnover, fuel oxidation and forearm substrate exchange in patients with thyrotoxicosis before and after medical treatment. [1996.04]
Prophylactic application of thyrostatic drugs during excessive iodine exposure in euthyroid patients with thyroid autonomy: a randomized study. [1996.03]
A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs. [1995.11]
Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients. [1995.05]
A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. [1993.06]
Adjunctive cholestyramine therapy for thyrotoxicosis. [1993.01]
Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. [1992.06.25]
Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism. [1992.06]
Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. [1991.11]
Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. [1991.04.04]
Other research related to Tapazole (Methimazole)
Choanal atresia associated with maternal hyperthyroidism treated with methimazole: a case-control study. [2008.09.15]
Effects of an anti-thyroid drug, methimazole, administration to rat dams on the cerebellar cortex development in their pups. [2008.08]
Effect of methimazole on warfarin anticoagulation in a case of Graves' disease. [2008.01]
Aplasia cutis congenita with skull defect in a monozygotic twin after exposure to methimazole in utero. [2007.10]
Methimazole-induced cholestatic jaundice in an elderly hyperthyroid patient. [2007.09]
Significance of thyroid blood flow as a predictor of methimazole sensitivity in untreated hyperthyroid patients with Graves' disease. [2007.09]
Lack of effect of methimazole on dendritic cell (DC) function and DC-induced Graves' hyperthyroidism in mice. [2007.07]
Propylthiouracil versus methimazole in treatment of Graves' disease during pregnancy. [2007.06]
[Effects of methimazole on the evolution of the allergic rhinitis of patients with Graves' disease] [2007.05]
[Methimazole and propylthiouracil induced acute toxic hepatitis] [2007.05]
Methimazole protects lungs during hepatic ischemia-reperfusion injury in rats: An effect not induced by hypothyroidism. [2007.05]
Generalised lymphadenomegaly associated with methimazole treatment in a hyperthyroid cat. [2007.03]
The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy. [2007.02]
Methimazole embryopathy: a contribution to defining the phenotype. [2007.02]
The relation of initial methimazole dose to the incidence of methimazole-induced agranulocytosis in patients with Graves' disease. [2007.02]
[Side effects after the usage of Chinese dieting product Meizitanc] [2007]
Other possibly related research studies
[Novel treatment of Graves' disease using the B-lymphocyte depleting agent rituximab] [2008.06.09]
Hyperthyroidism as a reversible cause of right ventricular overload and congestive heart failure. [2008.06.12]
Serum leptin and ghrelin levels in premenopausal women with stable body mass index during treatment of thyroid dysfunction. [2008.05]
Differential diagnosis and appropriate treatment of four thyrotoxic patients with Graves' disease required to take amiodarone due to life-threatening arrhythmia. [2008]
An alternative therapy for graves' disease: clinical effects and mechanisms of an herbal remedy. [2008.04]
A unique cell population in the mouse olfactory bulb displays nuclear beta-catenin signaling during development and olfactory sensory neuron regeneration. [2008.06]
Thyrotoxic myopathy mimicking myasthenic syndrome associated with thymic hyperplasia. [2008]
The prevalence of transient thyrotoxicosis after antithyroid drug therapy in patients with Graves' disease. [2008.01]
[Coincidence of Graves' disease and Angelman syndrome in a 13 month old boy] [2008.01]
The effect of anti-thyroid drug treatment duration on thyroid gland microvessel density and intraoperative blood loss in patients with Graves' disease. [2008.02]
Effects of adult dysthyroidism on the morphology of hippocampal neurons. [2008.04.09]
Childhood onset demyelination and Graves' disease: shared antigen or autoimmune clustering? [2007.11]
Effects of thyrotoxicosis and selective hepatic autonomic denervation on hepatic glucose metabolism in rats. [2008.03]
An investigation of predictors of renal insufficiency following treatment of hyperthyroidism in cats. [2008.04]
Graves' disease with intractable diarrhea, chylous ascites, and chylothorax: a case report. [2007.12]
Recurrent deep venous thrombosis during optimal anticoagulation and overt hyperthyroidism: a case report. [2007.12]
Treatment outcome of Graves' disease in Thai children. [2007.09]
Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves' disease. [2007.12]
An unusual etiology of erythropoietin resistance: hyperthyroidism. [2007]
Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study. [2007.12]
[Vasculitis with renal involvement and antineutrophil cytoplasmic antibodies (ANCA) in a child receiving benzylthiouracil] [2007.07]
|
